Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 29.06% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTRoivant Sciences Ltd.'s latest supported as-filed period reports revenue of $1.4M, 33.5% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 29.06% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -18758.95% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -33.55% · CORE
Level · gp.fundamentals.operating_margin
Raw value -25380.93% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 14009.43% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 5779.61% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Shares outstanding increased 5.8%; SBC / revenue moved 199261 bp higher.
2 evidence-backed componentsOperating margin changed -1225088 basis points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
ROIV · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001140361-26-036246SEC ↗8-KSep 8, 2026Period Sep 8, 20260001140361-26-035859SEC ↗4Sep 1, 2026Period Aug 28, 20260001140361-26-035375SEC ↗8-KAug 28, 2026Period Aug 28, 20260001140361-26-034854SEC ↗8-KAug 27, 2026Period Aug 27, 20260001140361-26-034735SEC ↗4Aug 24, 2026Period Aug 20, 20260001140361-26-034239SEC ↗4Aug 24, 2026Period Aug 20, 20260001140361-26-034238SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 8, 2026Filed Sep 10, 2026 | Fitzgerald MeghanDirector | Open Market SaleDirect | 20,000 | $40 | $798,000 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Fitzgerald MeghanDirector | Option ExerciseDirect | 20,000 | $9 | $176,000 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Fitzgerald MeghanDirector | Option ExerciseDirect | 20,000 | $0 | $0 | Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 | Venker EricPresident & Immunovant CEO | Open Market SaleDirect | 166,182 | $36 | $5.9M | Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed -32.4% from the comparable as-filed period.
Revenue changed -33.5% from the comparable as-filed period.
Free-cash-flow proxy changed -30.0% from the comparable as-filed period.
Operating income changed -28.5% from the comparable as-filed period.
Research & development changed +32.1% from the comparable as-filed period.
Capex / revenue changed -15689 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001140361-26-034066| Option ExerciseDirect |
| 200,000 |
| $4 |
| $770,000 |
| Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 | Venker EricPresident & Immunovant CEO | Option ExerciseDirect | 200,000 | $0 | $0 | Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 | Venker EricPresident & Immunovant CEO | Open Market SaleDirect | 33,818 | $36 | $1.2M | Form 4 ↗ |
| Aug 21, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Open Market SaleDirect | 144,756 | $36 | $5.3M | Form 4 ↗ |
| Aug 21, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Option ExerciseDirect | 144,756 | $0 | $0 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Option ExerciseDirect | 144,756 | $4 | $557,311 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 24, 2026 | Pulik RichardCFO | Tax WithholdingDirect | 5,749 | $37 | $211,793 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 24, 2026 | Venker EricPresident & Immunovant CEO | Tax WithholdingDirect | 13,909 | $37 | $512,408 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Option ExerciseDirect | 17,519 | $4 | $67,448 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Option ExerciseDirect | 17,519 | $0 | $0 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Open Market SaleDirect | 17,519 | $37 | $653,459 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Option ExerciseDirect | 172,899 | $0 | $0 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Option ExerciseDirect | 172,899 | $4 | $665,661 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 21, 2026 | Sukhatme MayukhPresident & CIO | Open Market SaleDirect | 172,899 | $37 | $6.4M | Form 4 ↗ |
| Aug 18, 2026Filed Aug 18, 2026 | Sukhatme MayukhPresident & CIO | Option ExerciseDirect | 31,801 | $4 | $122,434 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 18, 2026 | Sukhatme MayukhPresident & CIO | Option ExerciseDirect | 105,141 | $4 | $404,793 | Form 4 ↗ |